Literature DB >> 30457051

MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer.

Sumit Biswas1.   

Abstract

Since their discovery in the 1990's, the study of a class of non-coding, single-stranded RNAs, christened the microRNAs has opened up new vistas in the field of cancer biology. MicroRNAs bind to their target mRNAs to act as either oncogenes or tumour suppressors. With the near-complete elucidation of the biogenesis pathway, and the advent of rapid sequencing technologies, microRNAs have slowly cemented their place as essential biomarkers for delineating the progression, metastasis, relapse or drug resistance of cancer. Being crucial players in the cancer pathway, there has been considerable urgency in designing molecules - both at the nucleotide and non-nucleotide level to counter the effects of their binding. A number of different approaches have yielded quite a body of compounds which have been found to be effective in the treatment of various tumours across many different organs. In this study, the focus is on the review of the timeline of discovery and characterization of microRNAs, underlining their importance in different cancers, shedding light on the discovery of anti-microRNA compounds and illustrating their uses in deriving new strategies to combat cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  AntimiR; Biomarker; MicroRNA; RNA; Small molecule inhibitor; mRNA mimic.

Mesh:

Substances:

Year:  2018        PMID: 30457051     DOI: 10.2174/1568026619666181120121830

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

1.  Ultrasound-targeted microbubble destruction-mediated miR-767 inhibition suppresses tumor progression of non-small cell lung cancer.

Authors:  Xiaohua Li; Min Xu; Wenyu Lv; Xingwang Yang
Journal:  Exp Ther Med       Date:  2020-03-12       Impact factor: 2.447

2.  miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A.

Authors:  Fei Tian; Huihan Wang; Huanxin Ma; Yuan Zhong; Aijun Liao
Journal:  Int J Mol Med       Date:  2020-07-06       Impact factor: 4.101

Review 3.  Therapeutic Potential of Circular RNAs in Osteosarcoma.

Authors:  Ben Wan; Hao Hu; Renxian Wang; Weifeng Liu; Dafu Chen
Journal:  Front Oncol       Date:  2020-04-15       Impact factor: 6.244

4.  MiR-146a upregulates FOXP3 and suppresses inflammation by targeting HIPK3/STAT3 in allergic conjunctivitis.

Authors:  Hui Guo; Yongxin Zhang; Zifang Liao; Wenzhu Zhan; Yuan Wang; Yun Peng; Meina Yang; Xudai Ma; Guogan Yin; Lin Ye
Journal:  Ann Transl Med       Date:  2022-03

5.  Knockdown of the long non-coding RNA CACNA1G-AS1 enhances cytotoxicity and apoptosis of human diffuse large B cell lymphoma by regulating miR-3160-5p.

Authors:  Qiqi Zhou; Yan Zhang; Meiqing Zhao; Xia Zhao; Hongwei Xue; Shuxin Xiao
Journal:  Exp Ther Med       Date:  2022-08-18       Impact factor: 2.751

6.  A modified protocol for successful miRNA profiling in human precision-cut lung slices (PCLS).

Authors:  Monika Niehof; Stella Marie Reamon-Buettner; Olga Danov; Tanja Hansen; Katherina Sewald
Journal:  BMC Res Notes       Date:  2021-07-02

7.  MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9.

Authors:  Zhihua Liang; Jianhui Xu; Zhancheng Ma; Guihua Li; Wanhong Zhu
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

Review 8.  MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.

Authors:  Ozal Beylerli; Narasimha M Beeraka; Ilgiz Gareev; Valentin Pavlov; Guang Yang; Yanchao Liang; Gjumrakch Aliev
Journal:  Int J Mol Sci       Date:  2020-10-02       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.